Methylcobalamin and adenosylcobalamin are also available as oral (tablet) and injectable nutritional supplements without a prescription
The "K" denotes KPV, added to the GLOW base (GHK-Cu, BPC-157, TB-500)
This applies when practices obtain medications through Medicares discontinued CAP system or similar payer programmes

To Bromfenac 0.09%w/v , Moxifloxacin Hcl I.p Eq To Mocifloxacin 0.5%w/v, Benzalkonium Chloride Solution I.p 0.02%w/v (as Preservative) Sterile Aqueous Base FLOXISAF-L EYE DROP - MOXIFLOXACIN 0.5%W/V +LOTEPREDNOL ETABONATE 0.5% W/V HYDROXYLIS EYE DROP 10ML - Hydroxypropyl Methylecullose Ip 0.3%w/v , Phenylmercuric Nitrate Ip 0.01% W/v GATSIP EYE DROP - Gatifloxacin (0.3% w/v) LUMITRAV EYE DROP - TRAVOPROST(0.004%W/V) EYE DROP LOTESAQ DS EYE DROP - Loteprednol Etabonate (0.5% W/v) + Benzalkonium Chloride Sodium Ip (0.02% V/v) LOTESAQ LS EYE DROP - Loteprednol Etabonate (0.2% W/v) + Benzalkonium Chloride Sodium Ip (0.02% V/v) NIPASIN DS EYE DROP - NEPAFENAC (0.3%W/V) + STABLIZED OXYCHLORO COMPLEX (0.005%W/V) NIPASIN EYE DROP - Nepafenac (0.1% w/v) NAPHALIS CH EYE DROP - Naphazoline (0.1% W/v) + Chlorpheniramine Maleate (0.01% W/v) + Hydroxypropylmethylcellulose (0.25% W/v) NAPROVIT L DROP - MULTIVITAMIN, MULTI MINERAL & LYSIN DROP OPALAST EYE DROP OPALAST-OD EYE DROP -OLOPATADINE (0.2%W/V) EYE DROP OXASAFE EYE DROP - OFLOXACIN (0.3% WV) PREDCOTIL EYE DROP - Prednisolone (10mg) PAROFIN ORAL DROP - PARACETAMOL(125MG/ML) DROP PAROFIN PLUS DROP SILYTOIN M DROP - Silymarin (7mg) + Tricholine Citrate (25mg) + Lacithin(25mg) Multivitamin & Multiminerals TIMOLIS EYE DROP - TIMOLOL MALEATE 0.5% W/V TOBRASIL EYE / EAR DROP - TOBRAMYCIN (0.3%W/V) EYE DROP XYLOROL DS EYE DROP - Sodium Hyaluronate Bp (0.18% W/v) + Stabilized Oxychloro Complex (0.005% W/v) XYLOROL EYE DROP - SODIUM HYALURONATE 0.1%W/V TOBRASIL F EYE DROP - Fluoromethalone I.p

Afr J Biotechnol
However, as with any biological therapy, the theoretical possibility of individual hypersensitivity cannot be entirely eliminated, and appropriate monitoring remains prudent